A randomized trial assessing the utility of a test-dose program with taxanes

B. L. Stanford, S. R. Shah, E. E. Ballard, C. A. Jumper, Ian Rabinowitz, J. E. Dowell, W. C. Hunt, J. A. Krieger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel. Research design and methods: Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR. Results: Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane. Conclusion: Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.

Original languageEnglish (US)
Article number3130
Pages (from-to)1611-1616
Number of pages6
JournalCurrent Medical Research and Opinion
Volume21
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Taxoids
Hypersensitivity
docetaxel
Paclitaxel
Drug Costs
Incidence
Antineoplastic Agents
Research Design
Costs and Cost Analysis

Keywords

  • Docetaxel
  • Hypersensitivity reactions
  • Paclitaxel
  • Taxanes
  • Test dose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stanford, B. L., Shah, S. R., Ballard, E. E., Jumper, C. A., Rabinowitz, I., Dowell, J. E., ... Krieger, J. A. (2005). A randomized trial assessing the utility of a test-dose program with taxanes. Current Medical Research and Opinion, 21(10), 1611-1616. [3130]. https://doi.org/10.1185/030079905X65411

A randomized trial assessing the utility of a test-dose program with taxanes. / Stanford, B. L.; Shah, S. R.; Ballard, E. E.; Jumper, C. A.; Rabinowitz, Ian; Dowell, J. E.; Hunt, W. C.; Krieger, J. A.

In: Current Medical Research and Opinion, Vol. 21, No. 10, 3130, 10.2005, p. 1611-1616.

Research output: Contribution to journalArticle

Stanford, BL, Shah, SR, Ballard, EE, Jumper, CA, Rabinowitz, I, Dowell, JE, Hunt, WC & Krieger, JA 2005, 'A randomized trial assessing the utility of a test-dose program with taxanes', Current Medical Research and Opinion, vol. 21, no. 10, 3130, pp. 1611-1616. https://doi.org/10.1185/030079905X65411
Stanford, B. L. ; Shah, S. R. ; Ballard, E. E. ; Jumper, C. A. ; Rabinowitz, Ian ; Dowell, J. E. ; Hunt, W. C. ; Krieger, J. A. / A randomized trial assessing the utility of a test-dose program with taxanes. In: Current Medical Research and Opinion. 2005 ; Vol. 21, No. 10. pp. 1611-1616.
@article{8ae37363c4fe42818048456410923ab8,
title = "A randomized trial assessing the utility of a test-dose program with taxanes",
abstract = "Objective: Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel. Research design and methods: Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR. Results: Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5{\%} and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane. Conclusion: Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.",
keywords = "Docetaxel, Hypersensitivity reactions, Paclitaxel, Taxanes, Test dose",
author = "Stanford, {B. L.} and Shah, {S. R.} and Ballard, {E. E.} and Jumper, {C. A.} and Ian Rabinowitz and Dowell, {J. E.} and Hunt, {W. C.} and Krieger, {J. A.}",
year = "2005",
month = "10",
doi = "10.1185/030079905X65411",
language = "English (US)",
volume = "21",
pages = "1611--1616",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - A randomized trial assessing the utility of a test-dose program with taxanes

AU - Stanford, B. L.

AU - Shah, S. R.

AU - Ballard, E. E.

AU - Jumper, C. A.

AU - Rabinowitz, Ian

AU - Dowell, J. E.

AU - Hunt, W. C.

AU - Krieger, J. A.

PY - 2005/10

Y1 - 2005/10

N2 - Objective: Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel. Research design and methods: Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR. Results: Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane. Conclusion: Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.

AB - Objective: Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel. Research design and methods: Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR. Results: Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane. Conclusion: Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.

KW - Docetaxel

KW - Hypersensitivity reactions

KW - Paclitaxel

KW - Taxanes

KW - Test dose

UR - http://www.scopus.com/inward/record.url?scp=27144559659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144559659&partnerID=8YFLogxK

U2 - 10.1185/030079905X65411

DO - 10.1185/030079905X65411

M3 - Article

C2 - 16238901

AN - SCOPUS:27144559659

VL - 21

SP - 1611

EP - 1616

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

M1 - 3130

ER -